Global Hypercalcemia Treatment Market Growth (Status and Outlook) 2023-2029

Global Hypercalcemia Treatment Market Growth (Status and Outlook) 2023-2029

Hypercalcemia is a condition caused by above normal levels of calcium in the body, with serum calcium level greater than 2.6 mmol/L. It is a life threatening metabolic disorder associated with neoplastic diseases and occurs in 10% to 20% of all adults suffering from cancer; particularly lung and breast cancer, and myeloma.

LPI (LP Information)' newest research report, the “Hypercalcemia Treatment Industry Forecast” looks at past sales and reviews total world Hypercalcemia Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Hypercalcemia Treatment sales for 2023 through 2029. With Hypercalcemia Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hypercalcemia Treatment industry.

This Insight Report provides a comprehensive analysis of the global Hypercalcemia Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hypercalcemia Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hypercalcemia Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hypercalcemia Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hypercalcemia Treatment.

The global Hypercalcemia Treatment market size is projected to grow from US$ 8761.8 million in 2022 to US$ 15940 million in 2029; it is expected to grow at a CAGR of 8.9% from 2023 to 2029.

The increasing instances of surgical procedures, such as hip and knee replacements, will increase the risk of hypercalcemia and drive the growth prospects for the global hypercalcemia treatment market in the upcoming years. The study also shows that the prevalence of broken bone repair surgeries, cardiovascular procedures, percutaneous coronary interventions, joint replacement surgeries, knee replacement surgeries, hip replacement surgeries, and cases of coronary artery bypass grafting will increase the chances of developing hypercalcemia post surgeries. Consequently, the demand for hypercalcemia treatment drugs will also increase during the predicted period.

This report presents a comprehensive overview, market shares, and growth opportunities of Hypercalcemia Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Bisphosphonates
Glucocorticoids
Calcimimetic Agents

Segmentation by application
Mild Hypercalcemia
Moderate Hypercalcemia
Severe Hypercalcemia

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie
Amgen
Merck
Novartis
OPKO Health

Please note: The report will take approximately 2 business days to prepare and deliver.